GL1X · GenesisL1 explorer

Research workbench

Crystal structure of USP7 in complex with the covalent inhibitor, FT827

Analyse Crystal structure of USP7 in complex with the covalent inhibitor, FT827 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5NGF
Type
protein
Length
664 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ubiquitin carboxyl-terminal hydrolase 7
EC
3.4.19.12
UniProt
Q93009
Ligands
8WN
Pockets
8 · best druggability 0.69

Structure

x-ray diffraction · 1 distinct chain · 34% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BUbiquitin carboxyl-terminal hydrolase 7 (EC 3.4.19.12)protein33234% helix, 27% strandQ93009

Ligands and binding sites

  • 8WN · ~{N}-[2-[4-[4-[(1-methyl-4-oxidanylidene-pyrazolo[3,4-d]pyrimidin-5-yl)methyl]-4-oxidanyl-piperidin-1-yl]carbonylphenyl]phenyl]ethanesulfonamide · ligand · 2 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16050.690.7861empty
22280.610.81408WN
32070.570.79288WN
41150.430.7720empty
5900.390.7717empty

Interfaces

1 interface between chains.

  • A–B · 193 Ų buried · 0 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent, 1 disulfide (covalent ligand, disulfide).

Compared structures

  • 5NGF · Crystal structure of USP7 in complex with the covalent inhibitor, FT827 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.